DESCRIPTION:
IMPORTANT: This app is intended for use by qualified healthcare professionals only
DESCRIPTION:
IMPORTANT: This app is intended for use by qualified healthcare professionals only. Always seek the advice of a qualified clinician before making any medical or prescribing decisions.
Neuromuscular Drugs Reference is a comprehensive evidence-based drug reference for neuromuscular pharmacology. Built for neurologists, anaesthetists, intensivists, and allied health professionals managing patients with neuromuscular disease.
MYASTHENIA GRAVIS DRUGS
- Acetylcholinesterase inhibitors: pyridostigmine full dosing protocol, neostigmine IV use, propantheline for side effects, cholinergic crisis recognition (SLUDGE)
- Corticosteroids: prednisolone slow titration protocol, initial worsening warning (30-50%), bone and gastric protection, IV methylprednisolone for ICI toxicity
- Steroid-sparing agents: azathioprine with TPMT testing requirement, mycophenolate mofetil, ciclosporin — full monitoring table with pre-treatment tests, ongoing tests, and onset timelines
- Biologics: rituximab (anti-CD20, best in anti-MuSK MG), eculizumab (NICE TA6022 approved, meningococcal vaccination protocol), efgartigimod/Vyvgart (NICE 2022, IV and SC formulations), rozanolixizumab/Rystiggo (MHRA 2023), zilucoplan/Zilbrysq (MHRA 2023, daily SC)
NEUROMUSCULAR BLOCKERS
- Suxamethonium: RSI dosing, hyperkalaemia mechanism in denervated muscle, full contraindication list, malignant hyperthermia trigger
- Non-depolarising agents
- Reversal agents: sugammadex dosing (2/4/16mg/kg), why it is preferred over neostigmine in MG, neostigmine plus glycopyrrolate protocol, train-of-four monitoring principles
- Special populations: GBS, MG, renal failure, hepatic failure, burns, malignant hyperthermia, LEMS — drug choice table
GBS AND CIDP DRUGS
- IVIg: full dosing protocol for GBS and MG crisis, CIDP acute and maintenance dosing, start rates, brand information (Privigen, Kiovig, Flebogamma), IgA check requirement, pre-medication, AKI avoidance, side effects management table
- Plasma exchange: 5-session protocol, replacement fluid choice, contraindications, complications table (hypotension, hypocalcaemia, coagulopathy)
- CIDP maintenance: subcutaneous immunoglobulin (SCIg) with PATH trial evidence, Hizentra dosing, prednisolone protocol, PREDICT trial summary
- Supportive drugs
LAMBERT-EATON DRUGS
- Amifampridine (Firdapse)
- Pyridostigmine adjunct dosing in LEMS
- Malignancy screen protocol
- IVIg and plasma exchange in acute LEMS
BOTULINUM TOXIN
- All four UK licensed preparations
- Six therapeutic indications with doses
- Complications table:
STATIN MYOPATHY
- Full SAMS spectrum table
- Risk factors
- Rhabdomyolysis 6-step emergency protocol
- SANAM (statin-associated necrotising autoimmune myopathy)
- Statin re-introduction strategy
ICU NEUROMUSCULAR DRUGS
- NMBA indications, TOF monitoring principles, limiting duration to 24-48h
- Sedation agents:
- Opioids
- ICUAW prevention drug strategies
DRUG INTERACTIONS
- Comprehensive table of drugs worsening MG
- Drugs prolonging NMJ blocker duration
- Safe antiemetics in MG
- Antiemetics to AVOID in MG
INTERACTIVE FEATURES
- Drug search: 30+ searchable entries across all sections — tap result to navigate directly to the relevant section
- Quiz mode: 10 clinical pharmacology questions with detailed explanations covering all 9 sections
- My Notes: personal clinical notes saved during the session
- Font size adjustment: A- / A+ text scaling for bedside use
- 25+ tappable references including NICE TA6022, REGAIN trial, ADAPT trial, SID-GBS 2023, PATH trial, ACURASYS trial, PREEMPT trials, anti-HMGCR myopathy literature, BNF, MHRA drug safety updates
DISCLAIMER
This app is intended for use by qualified healthcare professionals only as a clinical decision-support and educational reference tool. It does not replace individual clinical assessment, local prescribing protocols or official prescribing information. Always consult the current BNF before prescribing.